DPT Laboratories helps to turn discovered drugs into developed and commercialized drugs. The contract manufacturer and developer makes prescription and over-the-counter (OTC) drugs, with an emphasis on semi-solid, liquid, and sterile formulations. Its products include aerosol foams, nasal sprays, eye drops, and creams, as well as metered inhalers, dosage vials, and prefilled syringes. The firm works with conventional and biological compounds and can manufacture small quantities for clinical trials or large batches for commercial production. It also provides development-stage analysis and testing services. DPT is owned by Renaissance Acquisition Holdings, which is being acquired by Mylan for $1 billion.